Non-Metastatic Castration Resistant Prostate Cancer Treatment Market Analysis

Therapy Type (Chemotherapy, Immunotherapy, Radiotherapy, Hormonal Therapy)

The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is segmented and analyzed for demand and supply by therapy type into chemotherapy, immunotherapy, radiotherapy, hormonal therapy, and others. Out of these types, the hormonal therapy segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the higher positive diagnosis rates and better efficiency of hormonal therapy than chemotherapy. Moreover, hormonal therapy is widely being used as an adjuvant treatment alongside radiation therapy and surgery, which is also projected to contribute to the growth of the segment during the forecast period. hormonal therapy has been observed to be the most effective method to stop or slow down the growth of cancer, especially, prostate and breast cancer since these types of cancers use hormones to grow. Hence, the higher prevalence of breast cancer is further expected to hike the segment growth over the forecast period. For instance, as of 2020, nearly 650,000 women lost their lives owing to breast cancer across the globe.

Application (General Medical & Surgical Hospitals, Specialty Hospitals, Clinics)

The global non-metastatic castration resistant prostate cancer (nmCRPC) treatment market is also segmented and analyzed for demand and supply by application into general medical & surgical hospitals, specialty hospitals, clinics, and others. The specialty hospitals segment is expected to lead the market over the forecast period. The growth of the segment can be attributed to the fact that nmCRPC is a relatively rare occurrence and as a result, a considerable portion of the population with this cancer on a global level tends to choose healthcare facilities specializing in its treatment. Since specialty is known to target one specific area of care and medicine and these hospitals are generally owned by physicians themselves. Specialty hospitals include cardiac facilities, orthopedic centers, and surgical centers. Hence, these are the hospital devoted to specialized care, enhanced and treatment of long-term illness, injury, cancer diagnostics, and infirmity. For instance, in the United States, the specialty hospital industry is anticipated to grow by approximately 2% in 2023 which sums up to around USD 60 billion. Hence, all these factors are projected to hike the market growth over the forecast period.

Our in-depth analysis of the global market includes the following segments: